Prader-Willi syndrome is a genetic disorder caused by changes to chromosome 15. It affects growth, behavior, and learning and requires continual management to avoid potentially life threatening ...

Discover five promising Prader-Willi syndrome therapies climbing the clinical ladder and nearing FDA approval in the coming ...

Prader-Willi syndrome is a genetic disorder that affects growth, behavior, and learning. There is no cure for the syndrome, but continual monitoring and treatment may improve a person’s quality of ...

After Heather Osterman’s son, Max, now 13, was born, she learned he had a genetic condition called Prader-Willi syndrome. While she and her husband were able to connect Max to all the therapies and ...

Findings showed DCCR significantly improved hyperphagia in patients with severe hyperphagia at baseline. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...

Affected populations: This genetic, multisystem disorder affects an estimated 1 in 30,000 to 1 in 10,000 people worldwide. Most cases of the syndrome occur sporadically, meaning the genetic changes ...

Please provide your email address to receive an email when new articles are posted on . Diazoxide choline extended-release is the first FDA-approved therapy to address hyperphagia in Prader-Willi ...

Every waking minute of Hannah Wilkinson’s day is filled with intense hunger. — -- Every waking minute of Hannah Wilkinson’s day is filled with intense hunger. “Even if she's just eaten, we can … ...

WE’LL TALK TO YOU LATER. WELL, IMAGINE EATING ENOUGH MAYBE TOO MUCH, BUT NEVER FEELING FULL. THAT’S WHAT A NORTHLAND TODDLER LIVES WITH EVERY DAY. AND THIS WORLD WHERE DISEASE DAY CAME DECISIONS DONNA ...

The FDA approved extended-release diazoxide choline (Vykat XR) to treat the intense persistent sensation of hunger in patients 4 years of age and older with Prader-Willi syndrome, maker Soleno ...

A new PDUFA target action date of March 27, 2025 has been set for the application. The Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for ...

CHATHAM, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated commercial-stage biotechnology company with innovative marketed products and a ...